New competitors have advanced, however. In June, Merck gained approval from the Food and Drug Administration for its latest shot, called Capvaxive. That vaccine protects against 21 serotypes, ...

Very pleased to be hosting Merck this afternoon. Joining us from the company, we have Rob Davis, who's the company's Chairman and CEO; and Dean Li, who is Head -- President of Merck Research ...

but Winrevair along with other assets could help soften the blow for Merck and potentially ensure that its revenue rises. A more modest growth catalyst is Capvaxive, which is a pneumococcal ...

and Merck & Co.’s newly approved Capvaxive targets 84%. Given the positive data, Mizuho analysts suggested that VAX-31 has the potential to displace Prevnar 20 and maybe even Capvaxive ...

The FDA recently approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) as the first pneumococcal conjugate vaccine designed to protect adults. For pediatric ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The best free logo maker lets you create eye-catching graphics to market your business completely free. Our team of creatives tested out the best logo makers and the best graphic design software ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Regulatory approvals for Merck's Capvaxive and Verona Pharma (NASDAQ:VRNA)'s Ohtuvayre are expected to significantly augment royalty revenue. Despite Takeda's Soticlestat failing to meet primary ...